Molecular Testing

  •  

    The Challenges of Using Artificial Intelligence to Improve Cancer Treatment

    With: Jeff Shrager, PhDRazelle Kurzrock, MD

    In a previous post, CureMatch co-founder Razelle Kurzrock, MD, told us all about her company’s artificial intelligence (AI) platform that matches patients with treatments based on their cancer’s molecular profile. Here, AI expert Jeff Shrager, PhD, responds, and Kurzrock offers a rebuttal. Shrager is Co-Founder and Director of Research at xCures, and was formerly Director of Research at Cancer Commons. He is also an… Read more »

  •   George Lundberg, MD

    Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

    Molecularly matched treatment for pancreatic cancer may extend life for some patients.

    Go to full article published by Medscape.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •  

    Using Artificial Intelligence to Match Combination Targeted Therapies in Oncology

    With: Razelle Kurzrock, MD

    A Q&A with Razelle Kurzrock, MD, Director of the Center for Personalized Cancer Therapy and the Rare Tumor Clinic at U.C. San Diego, and Co-Founder and Board Member of CureMatch, Inc. Email: razelle@curematch.com Q: The new understanding of many cancers brought about by molecular testing has led to a whole new field: precision oncology, which emphasizes targeted and immunotherapy. While promising, and sometimes spectacularly… Read more »

  •  

    Comprehensive Molecular Testing Needed for Stage IV Lung Cancer

    With: David Spigel, MD

    A Q&A with David Spigel, MD, Chief Scientific Officer, Director of the Lung Cancer Research Program, and Principal Investigator at Sarah Cannon Research Institute. Email: dspigel@tnonc.com Q: You are an expert medical oncologist with particular interest in lung cancer. The various forms of lung cancer are serious diagnoses, all potentially lethal malignancies. There are theoretical, investigational, and clinical justifications to perform molecular testing of… Read more »

  •   George Lundberg, MD

    Research paper from Nature curated by Editor in Chief George Lundberg, MD, who notes: 

    A massive study of thousands of cancers that explores the genomic basis for cancer is being reported simultaneously in dozens of journals. Nature has published this summary article.

    Go to full paper published in Nature.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from CAP Today curated by Editor in Chief George Lundberg, MD, who notes: 

    Tumor boards are an established method of dealing with problem cancer cases. In precision oncology, they may, even must, be molecular. This is a great example of how a molecular tumor board can provide actionable insights for patients.

    Go to full article published by CAP Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from The Journal of Urology curated by Editor in Chief George Lundberg, MD, who notes: 

    In this study, clinical and basic pathologic findings outperformed molecular typing in predicting outcomes of bladder cancer.

    Go to full paper published in The Journal of Urology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from JAMIA Open curated by Editor in Chief George Lundberg, MD, who notes: 

    This study found a virtual molecular tumor board to be efficient and effective for more than 1,000 patients.

    Go to full paper published in JAMIA Open.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •  

    Using Molecular Testing to Guide Treatment for Advanced Colorectal Cancer

    With: Kalpana Kannan, PhD

    A Q&A with Kalpana Kannan, PhD, former Scientist at Cancer Commons Q: Colorectal cancer is common, and although many cases in earlier stages are cured by surgery alone or with adjuvant chemotherapy, it is still a lethal threat for many patients. Nonetheless, several new targeted and immunotherapeutic agents are now available. When should patients receive molecular testing for their colorectal cancer, what information should… Read more »

  •   George Lundberg, MD

    Announcement from the College of American Pathologists curated by Editor in Chief George Lundberg, MD, who notes: 

    What forms of testing should be done for diffuse gliomas? In this announcement, a global panel invites comments about proposals.

    Go to full announcement published by the College of American Pathologists.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.